Discovery of Isotucaresol derivatives as adjuvants for vaccines testing in a SARS-CoV-2 vaccine model
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 75N93021C00054-0-9999-1
Grant search
Key facts
Disease
COVID-19Start & end year
20212023Known Financial Commitments (USD)
$598,808Funder
National Institutes of Health (NIH)Principal Investigator
Omer RasheedResearch Location
United States of AmericaLead Research Institution
N/AResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Vaccine design and administration
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
The long-term goal of the program is the commercial development of synthetic mimetics of novel saponin adjuvants that can be produces as single chemical entities on a large scale, are chemically more stable than current saponin adjuvants.